Laboratorios Roemmers SAICF data allegedly listed by Aurora ransomware group

• Ransomware group: Aurora
• Country: Argentina
• Sector: Healthcare
• Announcement date: October 1, 2026

Aurora ransomware group claims data breach at Laboratorios Roemmers SAICF

The threat group known as Aurora has listed data allegedly belonging to Laboratorios Roemmers SAICF on their leak site. The claim, announced on October 1, 2026, involves a significant volume of sensitive information. According to the group, the breach occurred on the same day the announcement was made, involving approximately 96 GB of data. The threat actor claims to have obtained sensitive employee personal data and pharmaceutical formulations, a move that may be intended to exert pressure on the organization by publishing this information. Publicly available information regarding this specific group remains limited.

Details of the alleged data leak

The scale of the alleged theft is substantial, with the group claiming to have accessed a wide variety of corporate and personal files. According to the leak claim, the data includes a range of sensitive information spanning employee records, medical history, and core business intelligence. The specific items mentioned in the claim include:

• National identity numbers (CUIL) for 4,207 employees
• Dates of birth
• Health insurance affiliations
• Psychotropic drug dispensing records
• COVID-19 health tracking logs
• Pre-employment medical exam results
• 82 GB of drug formulations
• 193 MB of supplier dossiers
• 14 GB of internal pricing strategy

This collection of data suggests a targeted effort to compromise both the personal privacy of the workforce and the intellectual property of the corporation.

About Laboratorios Roemmers SAICF

Laboratorios Roemmers SAICF is a leading pharmaceutical company based in Argentina. It operates in the fields of drug manufacturing, development, and marketing.

Impact assessment and industry implications

The exposure of the allegedly leaked data carries significant risks for all parties involved. For the employees of the organization, the theft of national identity numbers, dates of birth, and health insurance information may increase the risk of identity theft. Furthermore, the exposure of sensitive health records, such as psychotropic medication logs and COVID-19 health tracking data, could have negative consequences for the individuals involved.

From a corporate perspective, the publication of drug formulations and supply chain details may weaken the company's competitive advantage and create risks regarding intellectual property. The loss of 14 GB of internal pricing strategy and 193 MB of supplier dossiers further compounds the threat to the organization's market position. Additionally, the exposure of supplier information may create secondary risks for the company's business partners and could facilitate targeted phishing attacks against the supply chain.

The organization may also face legal proceedings under Argentine data protection regulations due to the nature of the exposed data. In such scenarios, organizations in the healthcare and pharmaceutical sectors typically focus on strengthening their defensive postures. This often involves implementing robust encryption for sensitive data at rest and in transit, enforcing strict access controls, and maintaining comprehensive logging and monitoring to detect unauthorized access. Furthermore, regular security awareness training is a common defensive step to mitigate the risk of phishing and other social engineering tactics that often precede such breaches.

The mechanics of ransomware and double extortion

While specific details regarding the ransom demand are not provided in this claim, the nature of the leak aligns with the